1

Investor Presentation

2022 Preliminary Results Presentation

"Building the base for Growth"

March 2023

Lar Malone Interim CFO

A World Leading Digital Health Platform for Injectable Medications

As many as 1-in-2 patients fail to adhere to their medication schedule.

Our technologies integrate with patient support programs to significantly improve adherence for individuals with at home therapy regimens

2023 will see accelerating growth driven by exceptional platform

2022 - build out of the commercial and operations infrastructure laying the foundation for growth in 2023 and beyond

Accelerating opportunity, particularly in the US, with Medicare reimbursement and Specialty

Pharmacy adoption of digital adherence tools underpinning significant growth prospects

Healthbeacon is very well positioned - in contract or late stage pre-contract with 5 SpecialityPharmacies giving us access to >60% of US Rx Volume. In contract with 4 Major Clinical Groups for access to Medicare Patients.

First product launch with Accredo Specialty Pharmacy to commence in Q2 2023, following by 2additional product launches with Speciality Pharmacy organisations through Q3 and Q4 2023

IPO proceeds and commercial partnerships provide the funding for this period of accelerating growth

Q1 2024 exit ARR of €25m expected

US Market Adoption

Large Specialty Pharmacy Network and Medicare (Reimbursement)

Major Injectable Launches across platform

Funded for those launches

Growth Inflection point driven by US clinic and pharmacy deals

Success underpinned by access to top tier client partners, peer reviewed evidence, to deliver accelerating growth at pace

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Healthbeacon plc published this content on 31 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 March 2023 08:03:09 UTC.